Equities analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post earnings per share of $5.61 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Regeneron Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $4.60 and the highest estimate coming in at $6.28. Regeneron Pharmaceuticals reported earnings per share of $5.23 in the same quarter last year, which indicates a positive year-over-year growth rate of 7.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, February 14th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $21.49 per share for the current financial year, with EPS estimates ranging from $20.08 to $22.29. For the next fiscal year, analysts forecast that the business will post earnings of $22.51 per share, with EPS estimates ranging from $19.08 to $26.69. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same period last year, the company earned $3.99 earnings per share. The business’s revenue was up 10.8% on a year-over-year basis.

Several research firms recently weighed in on REGN. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 23rd. Robert W. Baird cut shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Friday, August 3rd. TheStreet cut shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Tuesday, November 13th. Canaccord Genuity boosted their price target on shares of Regeneron Pharmaceuticals from $304.00 to $390.00 and gave the stock a “hold” rating in a report on Friday, August 3rd. Finally, SunTrust Banks restated a “hold” rating and set a $400.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and five have given a buy rating to the stock. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $402.37.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi sold 104,552 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, September 24th. The stock was sold at an average price of $388.65, for a total transaction of $777,300.00. Following the completion of the sale, the director now directly owns 13,000 shares in the company, valued at approximately $5,052,450. The disclosure for this sale can be found here. In the last ninety days, insiders sold 108,552 shares of company stock worth $44,081,027. Insiders own 12.42% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. Wrapmanager Inc. boosted its stake in Regeneron Pharmaceuticals by 9.9% during the second quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 130 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in shares of Regeneron Pharmaceuticals by 4.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after purchasing an additional 141 shares during the period. Traynor Capital Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 9.8% during the 2nd quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock valued at $572,000 after purchasing an additional 145 shares during the period. Cito Capital Group LLC increased its position in shares of Regeneron Pharmaceuticals by 4.3% during the 3rd quarter. Cito Capital Group LLC now owns 3,650 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 150 shares during the period. Finally, MUFG Securities EMEA plc increased its position in shares of Regeneron Pharmaceuticals by 1.7% during the 2nd quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock valued at $3,116,000 after purchasing an additional 152 shares during the period. 66.83% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals stock traded up $6.08 during midday trading on Friday, hitting $365.65. 696,714 shares of the stock were exchanged, compared to its average volume of 632,607. Regeneron Pharmaceuticals has a 52-week low of $281.89 and a 52-week high of $416.49. The stock has a market cap of $38.91 billion, a PE ratio of 27.27, a price-to-earnings-growth ratio of 1.54 and a beta of 1.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: What is the LIBOR?

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.